Savara (SVRA) Exchange Rate Effect (2011 - 2026)
Savara (SVRA) posted quarterly Exchange Rate Effect of $74000.0 for Q1 2026, up 346.67% year-over-year from $16567.2 in Q1 2025, and up 305.56% quarter-over-quarter from -$36000.0 in Q4 2025.
Savara (SVRA) Exchange Rate Effect (2011 - 2026) Analysis & Trends
Savara (SVRA) has reported Exchange Rate Effect for 12 consecutive years, with $74000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Exchange Rate Effect rose 346.67% year-over-year to $74000.0; the TTM figure through Mar 2026 stood at -$173000.0 (down 367.57% YoY), while the FY2025 annual figure was -$277000.0, down 5440.0% from the prior year.
- Exchange Rate Effect rose to $74000.0 in Q1 2026 per SVRA's latest filing, from -$36000.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $120000.0 in Q4 2022 and bottomed at -$145000.0 in Q3 2022.
- Historically, Exchange Rate Effect has averaged -$24470.6 across 5 years, with a median of -$30000.0 in 2025.
- Annual changes were most pronounced in 2025 — Exchange Rate Effect tumbled 1600.0% — and 2026, when it jumped 346.67%.
- Savara's Exchange Rate Effect stood at $120000.0 in 2022, then plunged by 73.33% to $32000.0 in 2023, then plunged by 318.75% to -$70000.0 in 2024, then surged by 48.57% to -$36000.0 in 2025, then jumped by 305.56% to $74000.0 in 2026.
- Business Quant data shows SVRA's Exchange Rate Effect at $74000.0 in Q1 2026, -$36000.0 in Q4 2025, and -$74000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | -30,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30,000.00 |
| Jun 30, 2026 | -30,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Dec 31, 2025 | -36,000.00 |
| Dec 31, 2025 | -36,000.00 |
| Sep 30, 2025 | -74,000.00 |
| Sep 30, 2025 | -74,000.00 |
| Jun 30, 2025 | -137,000.00 |
| Jun 30, 2025 | -137,000.00 |
| Mar 31, 2025 | -30,000.00 |
| Mar 31, 2025 | -30,000.00 |
| Dec 31, 2024 | -70,000.00 |
| Dec 31, 2024 | -70,000.00 |
| Sep 30, 2024 | 82,000.00 |
| Sep 30, 2024 | 82,000.00 |
| Jun 30, 2024 | -19,000.00 |
| Jun 30, 2024 | -19,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |